Educational Event about LISRAYA (brepocitinib)

The US Food and Drug Administration (FDA) has approved Lisraya™ (brepocitinib) for the treatment of adults with dermatomyositis (DM). This approval marks the the first oral therapy specifically indicated for dermatomyositis and the first targeted therapy approved for this rare autoimmune disease. Learn more on TMA blog and join our upcoming webinar, where you will hear from a patient, Veronica, about their experience taking LISRAYA and from a doctor who specializes in DM treatment. This webinar is sponsored by Priovant Therapeutics.

Speakers:

• Joshua C Prenner, MD – Joshua Prenner is an Assistant Professor of Clinical Dermatology at the Perelman School of Medicine at the University of Pennsylvania. He also serves as Assistant Program Director of the Dermatology-Rheumatology fellowship program as well as Assistant Director of the Penn Myositis Center and Medical Director of the Dermatology Infusion Center at the Hospital of the University of Pennsylvania. He completed an advanced fellowship in Dermatology-Rheumatology at Brigham and Women’s Hospital/Harvard Medical School, and is a graduate of Northwestern University’s combined Internal Medicine-Dermatology residency program. His clinical practice focuses on caring for patients with complex inflammatory and autoimmune skin diseases, particularly dermatomyositis, lupus, sclerosing disorders and psoriatic disease. His research explores how immune-targeted therapies can be used more safely and effectively, with the goal of improving treatments and quality of life for patients.
•  Veronica, taking LISRAYA – Veronica was diagnosed with dermatomyositis in 2021

Register Here